Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Pipeline Update Highlights 85 New Molecular Entities, 14 New Claims

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer will resubmit the NDA for its next-generation selective estrogen receptor modulator lasofoxifene in December with new data, the drug maker said in a pipeline update released Aug. 6

You may also be interested in...

Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas

As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said

Sanofi Will Establish Lovenox Follow-On In Series Of Head-To-Head Trials

Sanofi-Aventis is looking to establish its ultra low molecular weight heparin product AVE5026 - a follow-on to the firm's Lovenox - as more efficacious than enoxaparin in preventing venous thromboembolic events through a series of head-to-head trials against Lovenox

Pfizer parecoxib "not approvable"

Pfizer's injectable COX-2 inhibitor parecoxib is "not approvable" a second time, the firm says Sept. 20. Pfizer plans to meet with FDA "as soon as possible" to discuss the agency's concerns. The company added that "it disagrees with the conclusions" stated in the letter. Parecoxib, the pro-drug of Pfizer's Bextra (valdecoxib), was first deemed not approvable in July 2001 (1Pharmaceutical Approvals Monthly December 2001, p. 26). Parecoxib is marketed outside the U.S. as Dynastat. Another Pfizer drug, the osteoporosis treatment Oporia (lasofoxifene), also was deemed not approvable recently; the company announced receipt of the latter letter Sept. 13...





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts